Results and Ongoing Studies from the MFM Network
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
In the early 1970's, fetal monitoring technology escaped from the laboratory into the clinical environment in a rapid, almost chaotic sequence of events. The assumption upon which fetal monitoring was based was that most mental retardation and cerebral palsy occurs from lack of oxygen during labor, and is therefore preventable. We now that this assumption if false and the benefits of fetal monitoring are seemingly far less than originally hoped. In contrast, the NIH Maternal Fetal Medicine network is a very well designed approach to evaluating treatments before they become the standard of care. In this segment, Dr. Spong overviews some of the prior to currently active studies being conducted by this organization.
Overview
In the early 1970's, fetal monitoring technology escaped from the laboratory into the clinical environment in a rapid, almost chaotic sequence of events. The assumption upon which fetal monitoring was based was that most mental retardation and cerebral palsy occurs from lack of oxygen during labor, and is therefore preventable. We now that this assumption if false and the benefits of fetal monitoring are seemingly far less than originally hoped. In contrast, the NIH Maternal Fetal Medicine network is a very well designed approach to evaluating treatments before they become the standard of care. In this segment, Dr. Spong overviews some of the prior to currently active studies being conducted by this organization.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Updates From the 7th World Symposium Task Force
New Horizons: Unraveling Novel Therapies for Enhanced Cardiovascular Outcomes in Patients With Heart Failure
HF Management for Patients with Comorbid Conditions
Level Up Your Skills: Tailoring Management of HF
What do we know now that could have changed the history of CETP inhibition?: genetics and biology
mIDH Gliomas Explained: Characteristics and Management Strategies
Vorasidenib and mIDH Gliomas: Reviewing the Efficacy Data
Diagnosing and Treating Benign Prostatic Hyperplasia and Overactive Bladder
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?